dengu
viru
denv
member
flavivirida
famili
denv
infect
caus
dengu
fever
df
sever
form
diseas
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
denv
four
serotyp
capabl
caus
sever
diseas
frequenc
sever
geograph
spread
case
increas
past
decad
everi
year
one
hundr
million
new
case
df
dhfdss
estim
present
despit
intens
global
research
effort
vaccin
antivir
treatment
dengu
infect
avail
vaccin
develop
complex
due
multipl
factor
effect
vaccin
must
consist
tetraval
formul
protect
four
serotyp
one
serotyp
typic
circul
region
ii
subprotect
vaccin
potenti
increas
risk
vaccine
develop
sever
form
dengu
repeat
infect
known
associ
preexist
immun
sever
iii
sinc
infect
occur
develop
countri
ideal
vaccin
afford
fulli
protect
taken
togeth
vaccin
induc
robust
level
immun
ideal
one
inocul
requir
liveattenu
vaccin
replicationcompet
virus
induc
immun
respons
immun
memori
compar
induc
wildtyp
viru
liveattenu
virus
caus
diseas
low
level
replic
henc
low
level
inflamm
promin
exampl
success
liveattenu
vaccin
provid
longterm
immun
vaccinia
viru
polioviru
sabin
two
member
flavivirida
famili
yellow
fever
viru
japanes
enceph
viru
jev
liveattenu
denv
vaccin
shown
induc
protect
neutral
antibodi
titer
mice
monkey
human
addit
evid
balanc
cell
respons
contribut
protect
accumul
emphas
import
cell
epitop
vaccin
flavivirus
positivesens
singlestrand
rna
virus
flaviviru
genom
encod
structur
c
prm
e
nonstructur
protein
multifunct
protein
consist
rnadepend
rna
polymeras
methyltransferas
mtase
activ
respons
rna
cap
format
well
intern
rna
methyl
essenti
rna
translat
stabil
function
remain
elus
recent
other
demonstr
essenti
viral
replic
vitro
virus
bear
mutat
highli
conserv
mtase
catalyt
kdke
tetrad
sever
attenu
host
due
inabl
viru
shield
viral
rna
recognit
host
innat
immun
factor
denv
rna
bind
rigi
activ
interferon
ifn
product
via
cascad
involv
promot
stimul
ifn
turn
activ
ifn
stimul
gene
isg
induc
antivir
respons
infect
neighbour
cell
ifninduc
protein
tetratricopeptid
repeat
ifit
critic
inhibit
viral
infect
although
function
partial
understood
human
ifit
gene
famili
compris
four
member
wherea
mice
express
interestingli
ifit
homolog
conserv
amphibian
mammal
suggest
play
central
role
innat
immun
respons
bind
eukaryot
initi
factor
inhibit
translat
wherea
amplifi
antivir
signal
connect
result
ifn
product
role
human
less
well
understood
demonstr
denv
strain
bear
mutat
catalyt
site
replic
high
titr
cell
cultur
wherea
mutant
virus
highli
attenu
mice
rhesu
monkey
mutat
stabl
sever
passag
revers
wildtyp
wt
observ
safeti
improv
second
mutat
catalyt
tetrad
introduc
without
affect
viabil
viru
vitro
singl
dose
administr
rhesu
macaqu
rm
confer
protect
homolog
denv
challeng
mice
immun
singl
dose
dival
formul
mutant
virus
mice
immun
monoval
formul
show
compar
antibodi
respons
demonstr
interfer
two
serotyp
denv
mtase
mutant
moreov
enhanc
infect
increas
level
observ
immun
mice
upon
challeng
heterolog
viru
overexpress
ifit
hekdcsign
cell
suggest
role
attenu
mtase
mutant
human
cell
taken
togeth
result
demonstr
potenti
mutant
denv
vaccin
knowledg
first
liveattenu
ration
vaccin
approach
tailor
optim
activ
innat
adapt
immun
respons
sever
attenu
due
suscept
ifn
respons
flavivirus
replic
cytoplasm
cytoplasmrepl
virus
evolv
mtase
methyl
viral
mrna
cap
structur
previous
shown
west
nile
viru
wnv
mutat
asp
tetrad
kdke
complet
abolish
activ
lethal
viral
replic
mutat
three
residu
tetrad
abolish
decreas
led
attenu
virus
sinc
four
serotyp
denv
introduc
mtase
mutat
examin
whether
approach
feasibl
one
serotyp
wt
recombin
mtase
repres
ntermin
amino
acid
strain
clone
express
two
mutant
mtase
contain
alasubstitut
kdke
tetrad
fig
prepar
one
singl
mutat
anoth
doubl
mutat
mutant
enzym
retain
wt
activ
respect
neither
mutant
exhibit
activ
fig
cell
transfect
equal
amount
wt
mutant
genomelength
rna
gener
equival
number
viral
e
proteinexpress
cell
fig
wt
mutant
rna
produc
infecti
virus
passag
similar
plaqu
morpholog
fig
replic
mutant
virus
attenu
mammalian
vero
mosquito
cell
fig
continu
cultur
mutant
virus
vero
cell
cell
express
dcsign
hekdcsign
ten
round
day
per
round
chang
plaqu
morpholog
fig
data
shown
express
dcsign
facilit
denv
infect
sequenc
passag
virus
vero
hekdcsign
cell
show
engin
mutat
retain
supplementari
fig
similar
result
obtain
contain
mtase
equival
mtase
mutat
mtase
supplementari
fig
collect
result
demonstr
mutant
slightli
attenu
stabl
cell
cultur
infect
mice
wt
mutant
call
point
assess
viral
replic
immunogen
vivo
mice
lack
receptor
type
type
ii
ifn
use
wide
antivir
vaccin
test
mice
intraperiton
ip
infect
plaqueform
unit
pfu
wt
mutant
virus
viremia
result
show
mutat
mutat
attenu
viru
compar
wt
viru
fig
b
next
examin
combin
two
mtase
mutant
repres
address
potenti
competit
effect
describ
previous
attenu
strain
human
mice
end
mice
inject
ip
pfu
combin
total
pfu
virus
day
post
immun
mice
challeng
ip
pfu
wt
wt
denv
specif
igg
titer
viremia
observ
mice
immun
andor
protect
homolog
challeng
fig
demonstr
immun
respons
protect
even
though
igg
titer
andor
mice
time
lower
wt
virusinfect
mice
fig
e
gener
concern
live
attenu
vaccin
theoret
potenti
mutat
back
wt
pressur
immun
system
address
system
viru
mice
infect
mutant
isol
day
infect
mutat
found
stabl
supplementari
fig
rule
compensatori
mutat
introduc
viral
genom
input
output
day
infect
viru
sequenc
use
illumina
deep
sequenc
technolog
summar
supplementari
tabl
singl
nucleotid
polymorph
snp
respons
mutat
found
compar
sequenc
wildtyp
respect
next
compar
neutral
infect
enhanc
capac
serum
collect
day
post
immun
tabl
supplementari
fig
mutant
virus
caus
less
antibodydepend
enhanc
ade
respect
wildtyp
virus
heterolog
set
vs
immun
ade
test
vs
immun
ade
test
tabl
importantli
observ
enhanc
infect
vivo
fig
see
later
challeng
experi
virul
strain
data
suggest
vaccin
mutant
caus
ade
heterolog
challeng
even
though
lower
neutral
ab
titer
gener
mutant
strain
compar
wildtyp
viru
antibodi
crucial
reduc
viral
load
bind
neutral
viru
particl
cell
necessari
effici
viral
clearanc
mice
suitabl
studi
cell
respons
lack
signal
critic
activ
cell
therefor
use
ifnar
mice
lack
receptor
ifnar
mice
immun
pfu
wt
spleen
harvest
day
restimul
vitro
detect
product
fig
mutant
wt
viru
elicit
strong
cell
respons
restimul
respons
weaker
mice
like
due
lower
total
viral
load
mice
compar
mice
immun
wt
viru
fig
test
target
denv
cell
respons
splenocyt
restimul
pool
peptid
describ
yauch
et
al
signific
differ
cell
respons
seen
mice
immun
wt
fig
taken
togeth
denv
mutant
induc
cell
respons
epitop
present
similar
wt
infect
nevertheless
addit
studi
mice
monkey
necessari
assess
cell
respons
greater
detail
test
function
contribut
protect
strain
strain
caus
patholog
mice
test
protect
virul
strain
immun
mice
mixtur
wt
westpac
wt
pb
challeng
virul
strain
day
later
fig
protect
homolog
challeng
fig
immun
protect
mice
show
limit
crossprotect
infect
fig
enhanc
diseas
detect
heterolog
challeng
increas
level
associ
patholog
mous
model
context
ade
assess
possibl
adeassoci
patholog
measur
level
plasma
three
day
challeng
high
level
detect
unimmun
pb
mice
show
marker
patholog
independ
ade
immun
caus
ade
heterolog
challeng
data
demonstr
immun
protect
mice
challeng
aggress
virul
strain
caus
mortal
unimmun
mice
assess
safeti
viremia
profil
efficaci
neutral
antibodi
respons
protect
challeng
mutant
denv
vaccin
approach
immunolog
compet
host
three
group
rhesu
monkey
rm
immun
differ
dose
one
group
receiv
low
dose
pfu
one
group
medium
dose
pfu
one
group
high
dose
pfu
viru
viremia
monitor
day
inocul
viru
sever
attenu
viremia
detect
except
one
anim
receiv
high
dose
pfu
develop
low
viremia
tabl
viru
extract
sequenc
confirm
mutat
retain
viru
extract
day
anim
importantli
full
viru
genom
sequenc
viral
rna
recov
day
show
compensatori
mutat
introduc
data
shown
immun
monkey
develop
neutral
antibodi
day
immun
tabl
ade
analyz
assay
similar
enhanc
pattern
observ
heterolog
homolog
infect
vitro
ade
correl
neutral
titer
ie
higher
higher
enhanc
supplementari
fig
argu
physiolog
relev
infect
enhanc
would
expect
heterolog
infect
day
immun
monkey
includ
one
low
dose
immun
develop
high
titer
neutral
antibodi
tabl
monkey
challeng
pfu
wt
day
postimmun
viremia
detect
immun
monkey
wherea
four
pbsimmun
control
mean
peak
viru
titer
pfuml
mean
viremia
durat
day
tabl
anim
except
one
anamnest
antibodi
respons
observ
challeng
tabl
data
demonstr
live
attenu
denv
mtase
mutant
viru
even
administr
low
dose
pfu
induc
protect
immun
nonhuman
primat
cap
wnv
coronaviru
rna
function
subvert
innat
host
antivir
respons
escap
ifitmedi
suppress
assess
whether
true
denv
well
pretreat
hekdcsign
cell
increas
dose
h
hekdcsign
cell
suscept
type
ifn
produc
detect
level
infect
mutant
wt
viru
data
shown
cell
infect
wt
mutant
viru
significantli
sensit
pretreat
wt
viru
demonstr
percentag
infect
cell
fig
well
viral
titer
cultur
supernat
fig
test
stabil
mutat
ifn
pressur
differ
cell
type
passag
viru
presenc
uml
hekdcsign
illustr
supplementari
fig
lost
presenc
ifn
wherea
wildtyp
viru
resist
ifn
pressur
cell
line
isol
passag
three
hekdcsign
passag
one
isol
sequenc
mutat
retain
compensatori
mutat
introduc
data
shown
elucid
molecular
mechan
attenu
overexpress
human
hekdcsign
cell
cell
infect
wt
mutant
assess
number
infect
cell
flow
cytometri
fig
wt
viru
infect
affect
wherea
mutant
significantli
inhibit
howev
overexpress
complet
block
infect
affect
viru
output
infect
cell
fig
suggest
ifnmedi
signal
involv
respons
denv
mutant
wt
viru
show
similar
growth
kinet
untreat
cell
fig
current
nt
know
mutant
viru
attenu
vero
cell
hekdcsign
sinc
line
defici
ifn
product
note
maximum
antivir
effect
ifit
could
underestim
due
low
transfect
effici
ifitexpress
plasmid
compar
effect
mutat
viral
fit
mosquito
ae
aegypti
natur
transmiss
vector
denv
mosquito
fed
blood
contain
wt
mosquito
fed
titer
pfuml
signific
differ
oral
infect
dissemin
wt
mutant
virus
observ
day
postinfect
tabl
wt
viru
infect
mosquito
highest
titer
pfuml
mosquito
lower
titer
pfuml
oral
fed
pfuml
wt
viru
approxim
mosquito
infect
wt
viru
dissemin
mosquito
tabl
fed
pfuml
wt
viru
dissemin
rate
reach
contrast
mutant
viru
unabl
infect
ae
aegypti
subsequ
dissemin
observ
titer
tabl
examin
whether
mutant
could
replic
vivo
intrathorac
inocul
wt
mutant
virus
ae
aegypti
mosquito
intrathorac
inocul
bypass
mosquito
midgut
key
barrier
establish
infect
natur
feed
rout
wt
mutant
virus
reach
infect
rate
upon
intrathorac
inocul
mean
genom
copi
number
reach
respect
supplementari
fig
genom
copi
number
wt
viru
approxim
higher
mutant
viru
p
overal
result
demonstr
mutant
viru
compromis
vector
fit
variou
dengu
vaccin
strategi
current
develop
includ
live
attenu
viru
subunit
vaccin
chimer
virus
dna
vaccin
yfv
chimer
dengu
vaccin
develop
sanofipasteur
advanc
clinic
test
establish
revers
genet
manipul
denv
greatli
facilit
gener
promis
vaccin
candid
recent
progress
understand
mechan
attenu
mutant
flavivirus
provid
novel
approach
vaccin
antivir
develop
show
proofofconcept
studi
mtase
mutant
strain
stabl
vitro
safe
immunogen
vivo
importantli
enhanc
infect
observ
heterolog
infect
immun
mice
fear
clinic
set
subneutr
titer
antibodi
could
enhanc
infect
even
though
far
happen
context
vaccin
trial
human
commonli
use
approach
address
ade
vitro
infect
cell
presenc
antibodi
viru
alon
abl
infect
cell
effici
wherea
virusantibodi
immun
complex
bind
cell
via
receptor
assist
intern
viru
infect
cell
found
cell
could
infect
presenc
serum
immun
mice
monkey
dilut
approxim
neutral
system
supplementari
fig
line
previou
report
found
even
strongli
neutral
antibodi
enhanc
concentr
close
neutral
titer
clinic
relev
ade
would
expect
subneutr
titer
heterolog
infect
observ
experi
caveat
system
cell
express
inhibitori
present
human
target
cell
dendrit
cell
macrophag
neg
regul
ade
physiolog
amount
complement
anoth
neg
regul
ade
also
taken
account
summari
assay
done
show
ade
heterolog
infect
exclud
ade
limit
assay
potenti
ade
address
monkey
studi
live
attenu
dengu
vaccin
candid
sever
advantag
importantli
induc
long
last
humor
cellular
immun
respons
structur
nonstructur
viral
protein
studi
show
respons
peptid
similar
mice
immun
mutant
wt
viru
suggest
respons
qualit
equival
chimer
virus
use
backbon
four
denv
serotyp
glycoprotein
would
induc
typespecif
respons
restrict
structur
protein
one
denv
serotyp
interdepend
b
cell
respons
effici
gener
immun
memori
demonstr
number
human
studi
specul
advantag
attenu
nonchimer
denv
includ
natur
occur
b
cell
epitop
could
one
vaccin
requir
confer
longterm
immun
reinfect
seen
natur
denv
infect
singledos
vaccin
would
facilit
logist
vaccin
program
would
significantli
reduc
cost
compar
candid
requir
sever
booster
immun
mutant
denv
vaccin
approach
known
mechan
attenu
readili
gener
use
revers
genet
system
contrast
method
develop
live
attenu
vaccin
passag
wt
virus
cell
line
lead
introduct
random
mutat
revers
genet
systembas
ration
vaccin
ensur
vaccin
maintain
attenu
genotyp
addit
tetraval
formul
would
contain
attenu
mutat
four
serotyp
recombin
vaccin
strain
make
gener
pathogen
viru
intra
vaccinestrain
recombin
imposs
moreov
recombin
cell
cultur
hardli
observ
flavivirus
suggest
flavivirus
prone
evolut
recombin
introduc
addit
mutat
kdke
tetrad
safeti
attenu
achiev
viru
least
two
mutat
accept
clinic
set
data
demonstr
viru
attenu
mice
monkey
explain
fulli
mutant
viru
attenu
lower
viru
titer
compar
wt
viru
mice
unabl
respond
ifnsign
like
pattern
recognit
receptor
downstream
pathway
activ
mutant
viru
trigger
antivir
defens
mechan
ifndepend
ifnindepend
manner
whether
balanc
low
virul
high
immunogen
achiev
human
mutant
remain
elucid
studi
human
cell
show
increas
suscept
mutant
vitro
suggest
denv
mutant
attenu
human
well
monkey
immun
experi
one
monkey
four
high
dose
group
experienc
peak
viremia
pfu
compar
live
attenu
vaccin
candid
inde
weak
replic
vaccin
approach
desir
order
induc
strong
protect
cellular
immun
respons
replic
restrict
enough
preclud
onset
ill
wherea
subclin
symptom
mild
rash
transient
leukopenia
mildli
elev
liver
enzym
valu
gener
accept
furthermor
studi
murin
hepat
viru
shown
mtase
mutant
highli
attenu
natur
host
induc
ifn
could
induc
immunogen
vaccin
genet
stabl
vivo
moreov
replic
level
wnv
mutant
mice
larg
decreas
spleen
serum
brain
comparison
wt
wnv
infect
intracrani
inocul
pfu
mutant
wnv
caus
mortal
morbid
mice
demonstr
safeti
vaccin
approach
taken
togeth
evid
demonstr
safeti
immunogen
mtasemut
vaccin
approach
current
work
tetraval
formul
develop
strategi
toward
clinic
applic
experiment
procedur
involv
rhesu
monkey
approv
carri
strict
accord
guidelin
anim
experi
committe
state
key
laboratori
pathogen
biosecur
beij
china
procedur
perform
sodium
pentobarbit
anesthesia
train
technician
effort
made
amelior
welfar
minim
anim
suffer
accord
weatheral
report
use
nonhuman
primat
recommend
mous
experi
conduct
accord
rule
guidelin
agrifood
veterinari
author
ava
nation
advisori
committe
laboratori
anim
research
naclar
singapor
experi
review
approv
institut
review
board
biolog
resourc
center
singapor
iacuc
protocol
purchas
american
type
cultur
collect
http
wwwatccorg
cell
express
dcsign
obtain
lentivir
transfect
subsequ
cell
sort
cell
maintain
minim
essenti
medium
supplement
fetal
bovin
serum
wt
mtase
repres
ntermin
amino
acid
respect
clone
express
purifi
report
previous
mutagenesi
mtase
perform
use
quikchang
ii
xl
sitedirect
mutagenesi
kit
stratagen
complet
sequenc
mutant
mtase
verifi
dna
sequenc
assay
perform
describ
fulllength
infecti
cdna
clone
western
pacif
strain
strain
use
gener
wt
mutant
virus
standard
mutagenesi
protocol
use
engin
mutat
mtase
region
report
previous
protocol
vitro
transcript
rna
transfect
ifa
plaqu
assay
growth
kinet
report
previous
strain
describ
previous
femal
male
week
old
ifn
receptor
defici
mice
purchas
b
k
univers
limit
permiss
dr
aguet
isrec
school
life
scienc
ecol
polytechniqu
epfl
ifn
receptor
defici
mice
ifnar
background
provid
prof
ulrich
kalink
mice
bred
kept
specif
pathogenfre
condit
biomed
resourc
centr
singapor
immun
deriv
mutant
wt
virus
use
challeng
experi
denv
produc
cell
use
fourteen
rm
weigh
kg
prescreen
neg
igg
antibodi
denv
jev
indirect
immunofluoresc
assay
anim
randomli
divid
four
group
inocul
subcutan
sc
deltoid
region
left
arm
ml
dilut
contain
pfu
respect
anim
control
group
receiv
pb
blood
collect
rm
daili
post
immun
day
detect
viremia
neutral
antibodi
test
blood
taken
immun
day
day
postimmun
day
postimmun
immun
anim
includ
pbstreat
control
anim
challeng
sc
inocul
ml
contain
pfu
follow
day
blood
collect
determin
viremia
neutral
antibodi
level
serum
measur
standard
plaqu
reduct
neutral
test
day
postchalleng
respect
viremia
serum
sampl
determin
plaqu
assay
cell
monolay
plate
undilut
serum
serial
dilut
serum
inocul
onto
bhk
cell
h
adsorpt
well
overlaid
ml
dmem
supplement
fb
agaros
plate
incub
day
monolay
fix
addit
ml
formalin
solut
overlay
medium
h
fixat
room
temperatur
fix
remov
well
wash
water
monolay
stain
crystal
violet
methanol
plaqu
count
titer
express
pfuml
determin
dengu
virusneutr
antibodi
titer
serial
twofold
dilut
serum
start
dilut
mix
equal
volum
suspens
pfu
serumviru
mixtur
incub
h
test
mlwell
concentr
infecti
viru
use
plaqu
assay
describ
neutral
titer
defin
lowest
serum
dilut
infecti
viru
concentr
reduc
concentr
found
viru
incub
cultur
medium
cell
seed
per
well
plate
treat
hour
prior
infect
medium
vari
concentr
human
recombin
immunotool
cell
infect
moi
wt
mtase
mutant
viru
respect
incub
hour
harvest
process
flow
cytometri
describ
supernat
collect
plaqu
assay
ifit
express
plasmid
kind
gift
pichlmair
ifit
overexpress
cell
seed
per
well
plate
hour
later
cell
transfect
use
accord
manufactur
protocol
one
day
post
transfect
cell
trypsin
seed
plate
per
well
hour
incub
cell
infect
analys
describ
previous
transfect
rate
judg
parallel
experi
gfp
express
plasmid
determin
percentag
infect
cell
cell
harvest
wash
pb
fix
permeabil
cytofixcytoperm
bd
intracellular
dengu
e
protein
stain
antibodi
conjug
alexa
fluoresc
cell
measur
flow
cytometri
assess
ade
serumplasma
serial
dilut
constant
amount
viru
ad
antibodyviru
mixtur
incub
min
mixtur
ad
cell
per
well
moi
h
infect
rpmi
medium
contain
fc
ad
day
incub
infect
cell
fix
stain
intracellularli
percentag
infect
cell
quantifi
flow
cytometri
measur
neutral
heatinactiv
serumplasma
serial
dilut
constant
amount
viru
ad
antibodyviru
mixtur
incub
min
mixtur
ad
cell
atcc
stabli
transfect
human
dcsign
moi
h
infect
rpmi
medium
contain
fc
ad
incub
night
infect
cell
fix
stain
intracellularli
percentag
infect
cell
quantifi
flow
cytometri
data
analyz
graphpad
prism
softwar
calcul
spleen
harvest
day
infect
singl
cell
suspens
incub
live
viru
pool
follow
peptid
overnight
brefeldin
biolegend
ad
h
cell
wash
stain
antibodi
biolegend
cell
acquir
facscantoii
bectondickinson
data
analyz
flowjo
treestar
ltd
polystyren
plate
coat
concentr
heat
inactiv
dengu
viru
plate
incub
overnight
use
plate
wash
three
time
pb
ph
contain
pbst
nonspecif
bind
block
nonfat
dri
milk
dilut
pb
pbsm
h
room
temperatur
rt
wash
sera
dilut
pbsm
heat
inactiv
hour
threefold
serial
dilut
ad
well
plate
incub
h
rt
follow
three
wash
pbst
peroxidaseconjug
rabbit
antimous
igg
pbsm
ad
follow
h
incub
rt
three
addit
wash
pbst
tmb
use
enzym
substrat
reaction
stop
hcl
optic
densiti
read
nm
use
automat
elisa
plate
reader
endpoint
titer
defin
lowest
dilut
plasma
bind
twofold
greater
mean
bind
observ
neg
control
vector
compet
experi
perform
use
coloni
ae
aegypti
mosquito
popul
deriv
field
obtain
egg
month
batch
femal
mosquito
age
day
fed
pig
blood
contain
wt
mtase
mutant
titer
log
pfuml
fulli
engorg
mosquito
held
rel
humid
h
photoperiod
day
abdomen
separ
thorax
homogen
homogen
inocul
vero
cell
cultur
cultur
inocul
cell
day
viral
infect
assay
use
indirect
fluoresc
antibodi
test
ifa
antibodi
flaviviru
group
e
protein
dilut
provid
usa
cdc
mous
hybridoma
antimous
antibodi
conjug
fitc
use
primari
secondari
antibodi
respect
posit
fluoresc
determin
perform
manual
use
invert
fluoresc
microscop
olympu
chisquar
conting
tabl
statist
test
perform
detail
heterogen
vector
compet
withinbetween
wt
mutant
virus
intrathorac
inocul
wt
titer
pfuml
perform
use
femal
mosquito
follow
inocul
mosquito
held
seven
day
condit
describ
mosquito
kill
freez
homogen
viral
rna
quantifi
realtim
qrtpcr
use
primer
method
report
previous
briefli
whole
mosquito
homogen
viral
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
qrtpcr
complet
use
invitrogen
superscript
iii
platinum
onestep
qrtpcr
mix
without
rox
realtim
pcr
detect
system
biorad
cycl
paramet
perform
min
min
follow
cycl
sec
sec
twotail
unpair
ttest
perform
determin
statist
differ
mean
genom
equival
calcul
wt
mutant
virus
viru
isol
mous
serum
qiagen
viral
rna
extract
kit
fifti
ng
viral
rna
use
prepar
cdna
librari
use
illumina
truseq
rna
sampl
prepar
kit
accord
manufactur
protocol
protocol
modif
remov
mrna
enrich
step
cdna
librari
sequenc
multiplex
singl
lane
illumina
next
gener
sequenc
core
facil
genom
institut
singapor
one
million
bp
pairedend
read
gener
viru
wildtyp
mutant
viru
sampl
map
respect
refer
genom
use
bowti
map
statist
genotyp
call
made
samtool
data
analysi
perform
pipelin
pilot
http
wwwaccelryscom
least
two
read
altern
base
given
posit
defin
snp
statisit
test
perform
graphpad
prism
softwar
use
student
test
twoway
anova
chisquar
conting
tabl
statist
test
indic
figur
legend
